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Type 1 diabetic patients have increased risk of developing in-stent restenosis following endovascular stenting. Underlying
pathogenetic mechanisms are not fully understood partly due to the lack of a relevant animal model to study the effect(s) of
long-term autoimmune diabetes on development of in-stent restenosis. We here describe the development of in-stent restenosis
in long-term (∼7 months) spontaneously diabetic and age-matched, thymectomized, nondiabetic Diabetes Prone BioBreeding
(BBDP) rats (n = 6-7 in each group). Diabetes was suboptimally treated with insulin and was characterized by significant
hyperglycaemia, polyuria, proteinuria, and increased HbA1c levels. Stented abdominal aortas were harvested 28 days after stenting.
Computerized morphometric analysis revealed significantly increased neointima formation in long-term diabetic rats compared
with nondiabetic controls. In conclusion, long-term autoimmune diabetes in BBDP rats enhances in-stent restenosis. This model
can be used to study the underlying pathogenetic mechanisms of diabetes-enhanced in-stent restenosis as well as to test new
therapeutic modalities.
1. Introduction
In-stent restenosis (ISR) is the most common complica-
tion associated with coronary stenting and is histologically
characterized by occlusive neointima formation. As yet,
no adequate treatment modalities are available to treat
or prevent development of ISR [1–3]. The use of drug-
eluting stents has significantly reduced the incidence of ISR
when compared with bare metal stents, but also resulted in
increased rates of late stent thrombosis [4]. Diabetes mellitus
(DM) has been associated with increased risk to develop
(in-stent) restenosis both after percutaneous transluminal
coronary angioplasty as well as coronary stenting [5–14].
DM is a risk factor for ISR development after using both
drug-eluting and bare metal stents as revealed by various
meta-analyses (primarily including type 2 diabetic patients)
[15–17]. The beneficial effects on ISR of drug-eluting stents
over bare metal stents as observed in non-diabetic patients
appear to be less clear in diabetic patients. Although the
exact pathogenetic mechanism underlying increased ISR
development in diabetic patients is as yet unknown, it at least
appears to be due to an exaggerated neointimal response after
coronary stent placement as determined by intravascular
ultrasound [18]. Many studies thus favor for a deleterious
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effect of DM on the development of ISR, although the precise
magnitude of this effect is not clear. Especially age may act
as a confounder as older age is associated with increased
restenosis rates independent of DM [17].
To study the molecular and cellular mechanism(s) under-
lying DM-enhanced development of ISR, clinically relevant
animal models may be of great value. However, despite the
increasing numbers of diabetic patients worldwide together
with coronary artery disease being a significant source of
morbidity and mortality in these patients, relevant animal
models to study ISR are scarce. Although the Zucker diabetic
fatty (ZDF) rat has been used as a model to study type 2
DM-associated restenosis [19–21], a reliable model to study
the long-term effects of type 1 diabetes on ISR development
is still lacking. Whereas type 1 DM represents only 5–10%
of all diabetics it may be associated with severe coronary
artery disease at a relatively young age as demonstrated
in a selected population of type 1 diabetics eligible for
kidney and/or pancreas transplantation [22]. Various rodent
models of type 1 DM have been used to study the effects of
diabetes on mechanically induced restenosis in mice, rats,
or rabbits, in which diabetes is chemically induced using
streptozotocin or alloxan and in which contradicting results
were obtained [23]. In addition to rodent models, also
a streptozotocin-induced diabetes porcine model has been
used to study the development of ISR. In this model, a high
mortality rate (∼45%), a relatively short course of diabetes
(12 weeks), and most likely high costs may actually hamper
extensive use of this model [24]. Both streptozotocin and
alloxan are toxic compounds sharing structural similarities
with glucose which explains their selective uptake in cells
expressing the GLUT2 glucose transporter. As pancreatic ß-
cells have relatively high levels of GLUT2, streptozotocin
and alloxan are relatively, but not solely, toxic to ß-cells.
Because of the possible toxic side effects of these chemicals
and to model more accurately human type 1 (autoimmune)
DM, the availability of a spontaneous type 1 DM model
for the development of (in-stent) restenosis is needed. To
this end, we here describe the use of inbred Diabetes Prone
BioBreeding (BBDP/Wor) rats as a model to study diabetes-
enhanced development of ISR. Inbred BBDP rats are derived
from a Canadian colony of outbred Wistar rats (i.e., the BB
Wistar rat) in which diabetes developed spontaneously in the
1970s [25]. BBDP/Wor rats develop autoimmune diabetes
spontaneously due to severe lymphopenia and preferential
lack of immunoregulatory T cells [26–28]. Using the rat
abdominal aorta stenting model described previously [29],
we tested the hypothesis that long-term suboptimally treated
hyperglycaemic BBDP rats develop enhanced ISR compared
with non-diabetic age-matched control rats.
2. Materials and Methods
2.1. Rats. Specified pathogen-free Diabetes Prone BB
(BBDP/Wor) and Diabetes-Resistant (BBDR/Wor) rats were
bred at the Central Animal Facility of the University Medical
Center Groningen, University of Groningen, Groningen, The
Netherlands. Original breeding stocks were obtained from
Biomedical Research Models (BRM Inc., Worcester, MA,
USA). Rats were kept under clean conventional conditions
and were fed standard rat chow and acidified water ad libi-
tum. All animals received humane care in compliance with
the Principles of Laboratory Animal Care (NIH Publication
no. 85-23, revised 1996) and the Dutch Law on Experimental
Animal Care.
2.2. Diabetes Development in BBDP Rats. In the BBDP/Wor
colony maintained at the University Medical Center Gronin-
gen, 80–90% of the rats spontaneously develop diabetes from
∼70 days of age. Rats were considered diabetic when blood
glucose levels exceeded 15 mmol/L as measured in peripheral
blood obtained by tail vein puncture and by using a glucose
sensor (Accu-Chek Sensor Comfort, Roche Diagnostics
Nederland B.V., Almere, The Netherlands). In this study, 9
recent onset diabetic BBDP rats were initially included (both
male and female) which received a 1/2 (∼3-4 mm length)
Linplant sustained release insulin implant (LinShin Canada
Inc, Toronto, ON, Canada) subcutaneously at diagnosis
using a trocar. According to the manufacturer the implants
had an estimated insulin release of ∼1 U/24 h/(1/2) implant
for >40 days. We aimed at maintaining the blood glucose
values in insulin-treated diabetic rats between 15–20 mmol/L
during the entire follow-up period (up to 10 months of
age). During follow-up diabetic rats were weighed 2-3 times
a week. In case of weight loss, blood glucose levels were
measured as described above. When blood glucose levels
exceeded 20 mmol/L or blood glucose levels were between
15–20 mmol/L in the presence of substantial weight loss, rats
were reimplanted with an insulin implant as described above.
In addition to the insulin-treated diabetic BBDP rats
also a control group of age-matched non-diabetic BBDP rats
(initially n = 9) was included. Diabetes development was
prevented by performing thymectomy at the age of 21 days
as we described in detail elsewhere [30]. Weight and blood
glucose levels of thymectomized non-diabetic BBDP rats
were measured once every two weeks to obtain basal values.
2.3. HbA1c Measurements. To determine whether long-term
suboptimal insulin treatment of diabetic BBDP rats is asso-
ciated with increased glycated hemoglobin (HbA1c) levels
indicative of poor glycaemic control, we analyzed HbA1c
levels in a separate cohort of long-term diabetic BBDP
rats (n = 5), as well as in spontaneously protected non-
diabetic BBDP rats (n = 2) and non-diabetic BBDR/Wor rats
(n = 6). HbA1c levels were determined in freshly obtained
peripheral blood (tail vein puncture) using the BIO-RAD
in2it A1C analyzer (Bio-Rad Laboratories B.V., Veenendaal,
The Netherlands). Values are expressed as DCCT- HbA1c%.
2.4. Renal Function Measurements. Two weeks before stent-
ing renal function of the long-term diabetic and non-
diabetic BBDP rats was determined by housing the rats in
individual, urine-collecting metabolic cages for 24 hours and
by collection of blood plasma. Plasma and urine creatinine
levels were determined using the enzymatic colorimetric
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Table 1: Characteristics of the diabetic (DM) and thymectomized non-diabetic (non-DM) BBDP rats that were stented and evaluated for
the development of in-stent restenosis.
N
Gender♀/♂ Diabetes onset(median in days) Age at stenting(median in days) Diabetes duration at stenting(median in days) Serum creatinine
a
(mean ± SEM in μmol/L)
Non-DM BBDP 6 4/2 N.A.b 298 [270–412]c N.A.b 51 ± 7
DM BBDP 7 3/4 82 [72–140]c 270 [270–290]c 198 [150–204]c 56 ± 9
a
Serum creatinine levels were determined 2 weeks prior to stenting.
bN.A.: not applicable.
cValues between brackets indicate minimum and maximum values.
assay CREA plus (Roche Diagnostics GmbH, Mannheim,
Germany) [31]. Total urinary protein excretion was deter-
mined using the Roche Diagnostics Urinary/CSF Protein
assay (Roche Diagnostics GmbH, Mannheim, Germany)
[32, 33].
2.5. Stent Implantation. At a median diabetes duration of
28 weeks (7 months) 9 BBDP rats were stented in the
abdominal aorta as described previously [29]. As a control, 9
age-matched, thymectomized non-diabetic BBDP rats were
included. Briefly, under anesthesia (2% isoflurane (Abbott,
Hoofddorp, The Netherlands), 0.4 L/min O2 and 0.4 L/min
N2O) the abdominal cavity was opened. The aorta was
dissected, and surrounding connective tissue was removed.
Next, two vascular clips were placed onto the aorta distal
to the renal arteries and proximal to the aortic bifurcation.
A small incision was then made in the distal abdominal
aorta, and the balloon catheter was inserted and inflated
to 9 atm pressure to deploy a premounted 2.5 × 9 mm
BeStent 2 bare metal stent (Medtronic-Bakken Research,
Maastricht, The Netherlands). After deflation and removal
of the balloon, the aortic incision was closed with a 9-0
suture. Reperfusion was established by removing the clips,
and the abdomen was closed with 4-0 sutures. Starting
5 days before stenting until the end of the experiment,
rats were fed chow containing 0.33 mg clopidogrel/gram
chow (Plavix, Sanofi-Aventis, Gouda, The Netherlands) in
order to prevent platelet aggregation and to mimick the
human clinical setting. Four weeks after stenting, rats were
anesthesized and heparinized systemically with 500 IU i.v.
(Leo Pharma, Breda, The Netherlands). The stented aortas
were harvested, fixed in 4% formaldehyde, and embedded in
methyl metacrylate for further histological analysis. During
stenting, 3 non-diabetic control BBDP rats died because of
perforation of the aorta, resulting in an overall mortality of
17%. In addition, 2 stents from long-term diabetic BBDP rats
were lost during histological processing. Overall, stents from
7 diabetic and 6 non-diabetic BBDP rats were included for
histological analysis.
2.6. Quantification In-Stent Restenosis (ISR). To quantify the
severity of ISR, computerized morphometric analysis was
performed on Lawson (elastin) stained sections obtained
from the proximal, middle, and distal parts of each stent. The
neointimal area was calculated by measuring the total area
within the internal elastic lamina and the remaining lumen
using an Olympus BX-50F4 microscope equipped with an
Olympus c-3030 zoom digital camera and Olympus DP-Soft
version 3.0 software (Olympus, Tokyo, Japan). Total surface
neointima (in μm2) was then calculated by subtracting
surface remaining lumen from the total surface area within
the internal elastic lamina.
2.7. Quantification Vessel Injury. The mean vessel injury
score was determined as described previously [29] using
a method originally developed by Schwartz et al. [34].
Vessel injury at every stent strut within a cross-section
(9-10 struts/cross-section) was determined based on the
anatomic vessel structures penetrated by each strut. This
value ranged from 0 (least injury) to 3 (most injury). For
each cross-section the mean injury score was calculated.
From each stent 6–8 cross-sections (taken from the proximal,
middle, and distal parts of the stent) were analyzed. The total
mean injury score was expressed as the mean of the injury
scores of all cross-sections analyzed within one stent.
2.8. Statistical Analysis. Data are expressed as mean ± SEM.
Differences between two groups were analyzed for statistical
significance using an independent samples t-test. All P values
were two-tailed, and a P-value <.05 was considered statis-
tically significant. Statistical analyses were performed using
GraphPad Prism 5.00 for Windows (GraphPad Software Inc.,
USA).
3. Results
3.1. Glucose Homeostasis in Long-Term Diabetic BBDP Rats.
Diabetes incidence in the BBDP colony maintained at the
University Medical Center Groningen is 80–90%. Median
age of diabetes onset in the BBDP rats (n = 7) that
were stented and included for histological analysis was
82 days (Table 1). Insulin treatment using insulin-releasing
implants resulted in an almost permanent hyperglycaemic
state (blood glucose >8 mmol/L) in all diabetic rats. In
individual rats blood glucose oscillations were observed that
varied between 8 and 27 mmol/L. Depending on the blood
glucose levels (>20 mmol/L or 15–20 mmol/L in the presence
of substantial weight loss (>10% weight loss compared with
previous measurement)), rats received an insulin implant.
Time between reimplantations varied between 5 and 35 days.
As non-diabetic age-matched controls, 6 thymectomized
BBDP rats were included. Figure 1 shows the blood glucose
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Figure 1: Oscillations in blood glucose levels in a representative
diabetic (DM) BBDP rat treated with insulin pellets implanted
subcutaneously. During a follow-up period of 140 days the DM
BBDP rat received multiple insulin pellet implants (ips) guided
by rapid development of hyperglycaemia (solid line) and drop in
body weight (not shown). For comparison, glucose levels in an age-
matched thymectomized non-DM BBDP rat are shown. The grey
area indicates the normoglycaemic range (4–8 mmol/L).
oscillations observed in an individual diabetic and non-
diabetic BBDP rat during a time frame of 140 days during
which the diabetic rat received 9 insulin implants. The
median age at stenting was 270 and 298 days for the diabetic
and non-diabetic BBDP rats, respectively (not significantly
different), translating in a median diabetes duration of
198 days (Table 1). During the total follow-up period till
stenting mean blood glucose level after diabetes onset in
diabetic BBDP rats was 15.0 ± 0.4 mmol/L compared with
5.3± 0.1 mmol/L in thymectomized non-diabetic BBDP rats
(Figure 2(a), P < .001). As increased HbA1c levels have
been associated with increased cardiovascular risk in human
diabetics, we questioned whether long-term diabetes in our
BBDP rat model was also associated with increased HbA1c
levels. To this end, HbA1c levels were determined in a separate
group of long-term diabetic BBDP rats (n = 5) with a mean
diabetes duration of 249±50 days which was not statistically
different from the mean diabetes duration in the stented
BBDP rats (217±7 days) at sacrifice. For comparison, HbA1c
levels were determined in spontaneously protected non-
diabetic BBDP rats (n = 2) and non-diabetic BBDR/Wor rats
(n = 6). As shown in Figure 2(b), long-term diabetes resulted
in significantly increased HbA1c levels (11.9 ± 0.2 DCCT-
HbA1c%) compared with age-matched non-diabetic BB rats
(5.1± 0.1 DCCT-HbA1c%).
3.2. Renal Function in Long-Term Diabetic BBDP Rats. Two
weeks before stenting part of the long-term diabetic and non-
diabetic BBDP rats were housed in metabolic cages for 24 hrs
to collect urine. Long-term diabetes and the associated per-
manent hyperglycaemic state resulted in a 6-fold increased
(P < .001) urinary volume compared with non-DM
BBDP rats (Figure 3(a)). This was accompanied by severe
polydipsia (not shown). Furthermore, total urinary protein
excretion (Figure 3(b), P < .01) and urinary creatinine
excretion (Figure 3(c), P < .001) were significantly increased
in long-term DM BBDP rats compared with non-DM BBDP
rats. Increased urinary creatinine excretion in DM BBDP rats
suggests the presence of glomerular hyperfiltration which
is commonly observed in diabetics. Hyperfiltration was
supported by the slightly increased creatinine clearance rates
observed in the long-term DM rats (1.7 ± 0.3 mL/min in
DM versus 1.0 ± 0.2 mL/min in non-DM, not significant).
Despite the presence of proteinuria and hyperfiltration in
long-term DM BBDP rats, plasma creatinine levels in these
rats were similar to the levels detected in age-matched non-
DM BBDP rats indicating preserved renal function in the
presence of diabetes (Table 1). Histological analysis of PAS-
stained renal sections did not reveal increased interstitial and
glomerular matrix expansion in long-term DM BBDP rats
(not shown).
3.3. Enhanced In-Stent Restenosis in Long-Term Diabetic
BBDP Rats. In total, 18 rats (9 DM and 9 non-DM
BBDP rats) received a bare metal stent (Figure 4(a)) in the
abdominal aorta. During the stenting procedure, 3 non-DM
BBDP rats died because of perforation of the aorta (mortality
rate of 17%). Age of the DM and non-DM BBDP rats at
stenting was similar between both groups (Table 1, median
age, resp., 270 and 298 days, not significantly different).
Diabetes duration (median) in DM BBDP rats at stenting
was 198 days (Table 1). Stents were harvested 28 days after
stenting. Stents from 2 DM BBDP rats were lost during
histological processing. Finally, stents from 7 DM and 6 non-
DM BBDP rats were histologically analyzed for the severity
of ISR. At 28 days poststenting in both non-DM and DM
BBDP rats development of ISR was detected which was
characterized by neointima formation surrounding the stent
struts. Figures 4(d), 4(e), 4(f), and 4(g) show representative
photomicrographs of ISR in, respectively, non-DM and DM
BBDP rats. Quantitative analysis revealed that long-term DM
resulted in a 32% increase in surface neointima compared
with non-DM BBDP rats (Figure 4(b), P = .02). This
increase in neointima formation in DM BBDP rats was not
associated with an increased mean injury score (Figure 4(c),
P = .957).
4. Discussion
Diabetes mellitus (DM) is associated with increased risk
for the development of in-stent restenosis (ISR) [15–17].
Underlying pathogenetic mechanisms are as yet unknown,
and adequate treatment modalities are lacking. In order to
increase our insights into the molecular and cellular mech-
anism(s) underlying type 1 DM-enhanced development of
ISR a clinically relevant rodent model might be of great value.
Yet a model as such is not available. We therefore tested the
hypothesis that long-term spontaneously diabetic hypergly-
caemic BBDP rats develop enhanced ISR and may be used as
a suitable model to study the molecular and cellular mecha-
nism(s) involved in DM-enhanced development of ISR.
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Figure 2: Blood glucose and HbA1c levels are increased in long-term diabetic (DM) BBDP rats. (a) Average blood glucose level during the
entire follow-up period starting at diabetes onset until sacrifice (ranging from 150 to >200 days) (white bar). For comparison, mean blood
glucose levels in age-matched non-DM BBDP rats are shown (black bar). (b) Hyperglycaemia in long-term diabetic BBDP rats is associated
with increased glycated haemoglobin (HbA1c) levels (white bar) compared with non-DM rats (black bar). Data are expressed as the mean
± SEM (∗∗∗P < .001). Values within bars indicate the number of rats analyzed. DM: long-term diabetic BBDP rats, Non-DM: non-diabetic
rats.
DM Non-DM
0
25
50
75
100
U
ri
n
e/
24
h
rs
(m
L)
∗∗∗
7 3
(a)
DM Non-DM
0
10
20
30
P
ro
te
in
u
ri
a/
24
h
rs
(m
g)
∗∗
7 3
(b)
DM Non-DM
0
50
100
150
C
re
at
in
u
ri
a/
24
h
rs
(μ
m
ol
)
∗∗∗
7 3
(c)
Figure 3: Long-term diabetes in BBDP rats is associated with significant polyuria (a), proteinuria (b), and creatinuria (c). Two weeks prior
to stenting rats were housed in metabolic cages, and 24-hour urine samples were collected and analyzed as described in Section 2. Data are
expressed as mean ± SEM (∗∗P < .01, ∗∗∗P < .001). Values within bars indicate the number of rats analyzed. DM: long-term diabetic BBDP
rats, Non-DM: non-diabetic rats.
The hyperglycemic syndrome in BBDP rats develops
spontaneously due to a disturbed balance in autoreactive
and regulatory T cells [26–28]. The BBDP rat has been
suggested to represent the best rodent model for human type
1 DM as in this model diabetes manifests during adolescence
and involves an autoimmune disorder without the need of
exogenous intervention.
To achieve suboptimally controlled DM with manifest
hyperglycaemia and elevated HbA1c levels, recent onset dia-
betic BBDP rats were treated with insulin using slow release
insulin implants. By doing so, we were able to maintain DM
BBDP rats in a rather permanent hyperglycaemic state for
at least 8 months. The hyperglycaemic state was associated
with increased HbA1c levels as well as polyuria, polydipsia,
proteinuria, and glomerular hyperfiltration. Severity of
proteinuria was within the range reported by Cohen et al.
who also determined protein excretion in long-term DM
BBDP rats that were treated with daily insulin injections
[35]. As older age is associated with increased restenosis rates
independent of DM [17], for our study it was important
to include age-matched non-diabetic controls rather than
prediabetic young BBDP rats. In order to prevent diabetes
development in BBDP rats thymectomy was performed at
the age of 21 days as we described previously [30]. DM
and non-DM BBDP rats were followed for 7 months after
which they received a bare metal stent implanted in the
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Figure 4: Long-term diabetes in BBDP rats is associated with enhanced in-stent restenosis 4 weeks after stenting in the abdominal aorta.
(a) Photograph of a BeStent 2 bare metal stent used for implantation. The inflation balloon has been removed. (b) Surface area neointima
present 28 days after stenting in long-term DM (white bar) and non-DM (black bar) BBDP rats. (c) Mean injury score at 28 days after
stenting in long-term DM (white bar) and non-DM (black bar) BBDP rats. Data are expressed as the mean ± SEM (∗P < .05). Values
within bars indicate the number of rats analyzed. DM: long-term diabetic BBDP rats, Non-DM: non-diabetic rats. ((d), (e)) Representative
photomicrographs (Lawson staining) of stented abdominal aortas from a thymectomized non-diabetic (non-DM) BBDP rat 28 days after
stenting. ((f), (g)) Representative photomicrographs (Lawson staining) of stented abdominal aortas from a diabetic (DM) BBDP rat 28
days after stenting. (e) and (g) are high-power magnifications (magnification ×100) of the framed areas shown in, respectively, (d) and (f)
(magnification ×40). a: adventitia; m: media; ni: neointima; s: stent strut.
abdominal aorta. Our results clearly demonstrated that long-
term DM significantly enhanced the development of ISR by
32% compared with non-DM age-matched thymectomized
BBDP rats. This enhanced development of ISR in diabetic
BBDP rats was not associated with increased vascular injury,
that is, increased penetration of the stent struts through the
internal elastic lamina into the medial layer. The severity of
ISR was previously shown to be positively correlated with
the mean injury score [29]. However, in the same study we
demonstrated differences in severity of ISR between bare
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metal and sirolimus-eluting stents, which was independent
of the mean injury score. Our data suggest that T1DM
enhances the development of ISR by factors other than direct
vascular injury.
The current study was performed as a proof of concept
to demonstrate that long-term T1DM in BBDP rats indeed
enhances the development of ISR following stenting in the
abdominal aorta. Although we did not study the underlying
mechanism(s) of enhanced ISR in diabetic BBDP rats yet,
we suggest that long-term diabetes increases the proliferative
and migratory capacity of medial and neointimal smooth
muscle cells, thereby facilitating neointima formation [36,
37]. In addition, reduced endothelial repair capacity in
diabetic BBDP rats might have contributed to enhanced ISR
[38], but this needs to be determined.
The major advantage of the BBDP model to study
the development of ISR over other T1DM rodent models
is the fact that diabetes develops due to autoimmune-
mediated destruction of pancreatic islets without having the
toxic side effects of the use of streptozotocin or alloxan.
By using slow release insulin implants we showed that
long-term studies are feasible without the need of daily
insulin injections. A possible weakness of the model is
that BBDP rats are T cell lymphopenic and are, in that
respect, not fully immunocompetent. However, despite T cell
lymphopenia BBDP rats do develop autoimmune diabetes
which is mediated by autoreactive T cells indicating that
functional T cells are present in BBDP rats. Whether T
cells are pivotal in the development of ISR is however
unclear. Percutaneous transluminal coronary angioplasty has
been shown to induce T cell activation in a small cohort
of 10 patients with stable angina. Patients that developed
restenosis had higher T cell activation levels than patients
that did not develop restenosis [39]. However, treatment
with the calcineurin inhibitor cyclosporine to prevent T cell
activation did not reduce the development of restenosis in
rabbits [40]. We therefore assume that the presence of T cell
lymphopenia in BBDP rats has not been of major influence
on the development of ISR.
5. Conclusions
The BBDP rat model for type 1 diabetes is suitable for studies
on the long-term effects of hyperglycaemia on the develop-
ment of ISR. Long-term diabetes significantly increased the
development of ISR. To our opinion, future studies aiming at
the identification of the molecular and cellular mechanisms
involved as well as on testing the efficacy of novel therapeutic
interventions in this model are warranted.
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